MOLECULAR TYPE OF BREAST CANCER AS PROGNOSTIC FACTOR FOR METASTASIS
Introduction: The article provides an overview of the literature data on the peculiarities of metastasis of different subtypes of breast cancer (BC), which is characterized by heterogeneity, malignancy, early and rapid lymphatic and hematogenous metastasis. Modern studies have shown about the connection between the molecular type and localization of metastatic breast cancer.
Objective: Analysis of published data about the features of different molecular subtypes of breast cancer metastasis.
Materials and Methods: publications searched in the following databases: PubMed Medline, Health star, Embase, Cochrane depth from 2000 to 2016.
Results: Recent studies about metastatic breast cancer at the molecular types suggest that risk stratification by subtypes can provide a more personalized, individual care for certain high-risk groups metastasis. A literature review showed that the breast cancer subtypes have characteristics significantly different metastasis and life expectancy after the onset of local and distant metastases.
Conclusions: These molecular genetic studies reflect the primary risk and susceptibility of certain subtypes of breast cancer to metastasize to specific organs, which means determining the prognostic significance of molecular subtypes of breast cancer metastasis to further search
Aizhan A. Abiltaeva 1, http://orcid.org/0000-0002-0172-9202
Tasbolat A. Adylhanov 2, http://orcid.org/0000-0002-9092-5060
Ayan O. Myssayev 3, http:// orcid.org/0000-0001-7332-4856
State Medical University of Semey, Semey, Kazakhstan
1,2 Department of Oncology and visual diagnostics;
3 Public Health Department
1. Андреяшкина И.И. Оптимизация лечения рака молочной железы с метастазами в легкие с учетом факторов прогноза: дис. ...канд.мед.наук. Ростов-на-Дону, 2013. P. 199.
2. Возный Э.К. Cпециальные клинические ситуации: метастазы в легкие, плевру, печень, головной мозг // Практическая онкология. 2000. Vol. 2. P. 38.
3. Сафаров Б.И. Метастатическое поражение головного мозга // Материалы третьего съезда нейрохирургов Украины. 2003. P. 137.
4. Харченко В.П. МРТ в диагностике метастатического поражения костного скелета и оценке эффективности их лечения. Москва, 2007. P. 334–335.
5. Anders C.K., Carey L.A. Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer // Clin. Breast Cancer. NIH Public Access, 2009. Vol. 9 Suppl 2, № Suppl 2. P. S73–S81.
6. Anyanwu S.N.C. Temporal trends in breast cancer presentation in the third world // J. Exp. Clin. Cancer Res. 2008. Vol. 27. P. 19.
7. Aziz M.H. et al. Suppressing NRIP1 inhibits growth of breast cancer cells in vitro and in vivo // Oncotarget. Impact Journals, LLC, 2015. Vol. 6, № 37. P. 39714–39724.
8. Barnholtz-Sloan J.S. et al. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System // J. Clin. Oncol. 2004. Vol. 22, № 14. P. 2865–2872.
9. Cardoso F. Metastatic breast cancer patients: The forgotten heroes! // The Breast. 2009, Vol. 18. P. 271–272.
10. Carey L.A. et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study // JAMA. 2006. Vol. 295, № 21. P. 2492.
11. Carney W.P. et al. HER-2/neu diagnostics in breast cancer // Breast Cancer Res. BioMed Central, 2007. Vol. 9, № 3. P. 207.
12. Chang J. et al. Survival of patients with metastatic breast carcinoma // Cancer. Wiley Subscription Services, Inc., A Wiley Company, 2003. Vol. 97, № 3. P. 545–553.
13. Chia S.K. et al. The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer // Cancer. 2007. Vol. 110, № 5. P. 973–979.
14. Chiang A.C., Massagué J. Molecular basis of metastasis // N. Engl. J. Med. NIH Public Access, 2008. Vol. 359, № 26. P. 2814–2823.
15. Colzani E. et al. Time-dependent risk of developing distant metastasis in breast cancer patients according to treatment, age and tumour characteristics // Br. J. Cancer. Nature Publishing Group, 2014. Vol. 110, № 5. P. 1378–1384.
16. Dent R. et al. Pattern of metastatic spread in triple-negative breast cancer // Breast Cancer Res. Treat. 2009. Vol. 115, № 2. P. 423–428.
17. Dent R. et al. Time to disease recurrence in basal-type breast cancers // Cancer. Wiley Subscription Services, Inc., A Wiley Company, 2009. Vol. 115, № 21. P. 4917–4923.
18. Dent R. et al. Triple-negative breast cancer: clinical features and patterns of recurrence // Clin. Cancer Res. 2007. Vol. 13, № 15 Pt 1. P. 4429–4434.
19. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) K. et al. Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials // Lancet (London, England). Elsevier, 2015. Vol. 386, № 10001. P. 1353–1361.
20. Figueroa-Magalhães M.C. et al. Treatment of HER2-positive breast cancer // The Breast. 2014. Vol. 23, № 2. P. 128–136.
21. French Adjuvant Study Group. Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial // J. Clin. Oncol. 2001. Vol. 19, № 3. P. 602–611.
22. Hess K.R. et al. Metastatic patterns in adenocarcinoma // Cancer. Wiley Subscription Services, Inc., A Wiley Company, 2006. Vol. 106, № 7. P. 1628.
23. Hicks D.G. et al. Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR // Am. J. Surg. Pathol. 2006. Vol. 30, № 9. P. 1097–1104.
24. Kennecke H. et al. Metastatic behavior of breast cancer subtypes // J. Clin. Oncol. 2010. Vol. 28, № 20. P. 3274.
25. Kriege M. et al. Distant disease-free interval, site of first relapse and post-relapse survival in BRCA1- and BRCA2-associated compared to sporadic breast cancer patients // Breast Cancer Res. Treat. Springer US, 2008. Vol. 111, № 2. P. 303–311.
26. Lecouvet F.E. et al. Magnetic resonance imaging of the axial skeleton for detecting bone metastases in patients with high-risk prostate cancer: diagnostic and cost-effectiveness and comparison with current detection strategies // J. Clin. Oncol. 2007. Vol. 25, № 22. P. 3281–3287.
27. Lin N.U., Winer E.P. Advances in Adjuvant Endocrine Therapy for Postmenopausal Women // J. Clin. Oncol. American Society of Clinical Oncology, 2008. Vol. 26, № 5. P. 798–805.
28. Mayer M. et al. Evaluating the needs of women living with metastatic breast cancer: A global survey // The Breast. 2009. Vol. 18. P. 70.
29. Mayer M. et al. Importance of Providing Tailored Resources to Patients with Metastatic Breast Cancer: Results of the Global BRIDGE Survey // Cancer Res. American Association for Cancer Research, 2009. Vol. 69, № 24 Supplements. P. 3085–3085.
30. Nielsen T.O. et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma // Clin. Cancer Res. 2004. Vol. 10, № 16. P. 5367–5374.
31. Niwińska A., Murawska M., Pogoda K. Breast cancer brain metastases: differences in survival depending on biological subtype, RPA RTOG prognostic class and systemic treatment after whole-brain radiotherapy (WBRT) // Ann. Oncol. 2010. Vol. 21, № 5. P. 942–948.
32. O’Shaughnessy J. Extending survival with chemotherapy in metastatic breast cancer // Oncologist. 2005. Vol. 10, № 3. P. 21.
33. Olson E.M. et al. Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era // The Breast. NIH Public Access, 2013. Vol. 22, № 4. P. 525–531.
34. Parker J.S. et al. Supervised risk predictor of breast cancer based on intrinsic subtypes // J. Clin. Oncol. 2009. Vol. 27, № 8. P. 1160–1167.
35. Perou C.M. et al. Molecular portraits of human breast tumors // Nature. 2000. Vol. 406, № 6797. P. 747–752.
36. Quigley M.R. et al. The shifting landscape of metastatic breast cancer to the CNS // Neurosurg. Rev. 2013. Vol. 36, № 3. P. 377–382.
37. Robbins, S.L., Kumar, V., Cotran R.S. Robbins and Cotran pathologic basis of disease. 8th ed. Saunders, Philadelphia, PA, 2010. P. 1368.
38. Savci-Heijink C.D. et al. Retrospective analysis of metastatic behaviour of breast cancer subtypes // Breast Cancer Res. Treat. Springer, 2015. Vol. 150, № 3. P. 547–557.
39. Schrama J.G. et al. Randomized trial of high-dose chemotherapy and hematopoietic progenitor-cell support in operable breast cancer with extensive lymph node involvement: final analysis with 7 years of follow-up // Ann. Oncol. Oxford University Press, 2002. Vol. 13, № 5. P. 689–698.
40. Slamon D.J. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 // N. Engl. J. Med. 2001. Vol. 344, № 11. P. 783–792.
41. Smid M. et al. Subtypes of breast cancer show preferential site of relapse // Cancer Res. 2008. Vol. 68, № 9. P. 3109.
42. Sørlie T. et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications // Proc. Natl. Acad. Sci. U. S. A. 2001. Vol. 98, № 19. P. 10869–10874.
43. Voduc K.D. et al. Breast cancer subtypes and the risk of local and regional relapse // J. Clin. Oncol. 2010. Vol. 28, № 10. P. 1684–1691.
44. Weil R.J. et al. Breast cancer metastasis to the central nervous system // Am. J. Pathol. Elsevier, 2005. Vol. 167, № 4. P. 913–920.
45. Witzel I. et al. Breast cancer brain metastases: biology and new clinical perspectives // Breast Cancer Res. BioMed Central, 2016. Vol. 18, № 1. P. 8.
References:
1. Andreyashkina I.I. Optimizatsiya lecheniya raka molochnoi zhelezy s metastazami v legkie s uchetom faktorov prognoza: dis. ...kand.med.nauk [Optimization of treatment of breast cancer with metastases in the lungs, taking into account the forecast factors: Cand. Diss.]. Rostov-na-Donu, 2013. P. 199.
2. Voznyi E.K. Cpetsial'nye klinicheskie situatsii: metastazy v legkie, plevru, pechen', golovnoi mozg [Special clinical situations: metastases to the lung, pleura, liver, brain]. Prakticheskaya onkologiya [Practical Oncology ]. 2000, Vol. 2. P. 38.
3. Safarov B.I. Metastaticheskoe porazhenie golovnogo mozga [Metastatic brain damage]. Materialy tret'ego s"ezda neirokhirurgov Ukrainy [Materials of III congress of neurosurgeon of Ukraine]. 2003. P. 137.
4. Kharchenko V.P. MRT v diagnostike metastaticheskogo porazheniya kostnogo skeleta i otsenke effektivnosti ikh lecheniya [MRI in the diagnosis of metastatic skeletal lesions and evaluating the effectiveness of their treatment]. Materialy Vserossiiskogo kongressa luchevykh diagnostov [Materials of All-Russion congress of Radiologists] Moscow, 2007. P. 334-335.
5. Weil R.J. et al. Breast cancer metastasis to the central nervous system. Am. J. Pathol. Elsevier, 2005. Vol. 167, № 4. P. 913–920.
6. Anders C.K., Carey L.A. Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. Clin. Breast Cancer. NIH Public Access, 2009. Vol. 9 Suppl 2, № Suppl 2. P. S73–S81.
7. Anyanwu S.N.C. Temporal trends in breast cancer presentation in the third world. J. Exp. Clin. Cancer Res. 2008. Vol. 27. P. 19.
8. Aziz M.H. et al. Suppressing NRIP1 inhibits growth of breast cancer cells in vitro and in vivo. Oncotarget. Impact Journals, LLC, 2015. Vol. 6, № 37. P. 39714–39724.
9. Barnholtz-Sloan J.S. et al. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J. Clin. Oncol. 2004. Vol. 22, № 14. P. 2865–2872.
10. Cardoso F. Metastatic breast cancer patients: The forgotten heroes! The Breast. Vol. 18. P. 271–272.
11. Carey L.A. et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006. Vol. 295, № 21. P. 2492.
12. Carney W.P. et al. HER-2/neu diagnostics in breast cancer. Breast Cancer Res. BioMed Central, 2007. Vol. 9, № 3. P. 207.
13. Chang J. et al. Survival of patients with metastatic breast carcinomaю. Cancer. Wiley Subscription Services, Inc., A Wiley Company, 2003. Vol. 97, № 3. P. 545–553.
14. Chia S.K. et al. The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer. 2007. Vol. 110, № 5. P. 973–979.
15. Chiang A.C., Massagué J. Molecular basis of metastasis. N. Engl. J. Med. NIH Public Access, 2008. Vol. 359, № 26. P. 2814–2823.
16. Colzani E. et al. Time-dependent risk of developing distant metastasis in breast cancer patients according to treatment, age and tumour characteristics. Br. J. Cancer. Nature Publishing Group, 2014. Vol. 110, № 5. P. 1378–1384.
17. Dent R. et al. Pattern of metastatic spread in triple-negative breast cancer. Breast Cancer Res. Treat. 2009. Vol. 115, № 2. P. 423–428.
18. Dent R. et al. Time to disease recurrence in basal-type breast cancers. Cancer. Wiley Subscription Services, Inc., A Wiley Company, 2009. Vol. 115, № 21. P. 4917–4923.
19. Dent R. et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin. Cancer Res. 2007. Vol. 13, № 15 Pt 1. P. 4429–4434.
20. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) K. et al. Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet (London, England). Elsevier, 2015. Vol. 386, № 10001. P. 1353–1361.
21. Figueroa-Magalhães M.C. et al. Treatment of HER2-positive breast cancer. The Breast. 2014. Vol. 23, № 2. P. 128–136.
22. French Adjuvant Study Group. Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial. J. Clin. Oncol. 2001. Vol. 19, № 3. P. 602–611.
23. Hess K.R. et al. Metastatic patterns in adenocarcinoma. Cancer. Wiley Subscription Services, Inc., A Wiley Company, 2006. Vol. 106, № 7. P. 1628.
24. Hicks D.G. et al. Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR. Am. J. Surg. Pathol. 2006. Vol. 30, № 9. P. 1097–1104.
25. Kennecke H. et al. Metastatic behavior of breast cancer subtypes. J. Clin. Oncol. 2010. Vol. 28, № 20. P. 3274.
26. Kriege M. et al. Distant disease-free interval, site of first relapse and post-relapse survival in BRCA1- and BRCA2-associated compared to sporadic breast cancer patients. Breast Cancer Res. Treat. Springer US, 2008. Vol. 111, № 2. P. 303–311.
27. Lecouvet F.E. et al. Magnetic resonance imaging of the axial skeleton for detecting bone metastases in patients with high-risk prostate cancer: diagnostic and cost-effectiveness and comparison with current detection strategiesю. J. Clin. Oncol. 2007. Vol. 25, № 22. P. 3281–3287.
28. Lin N.U., Winer E.P. Advances in Adjuvant Endocrine Therapy for Postmenopausal Womenю J. Clin. Oncol. American Society of Clinical Oncology, 2008. Vol. 26, № 5. P. 798–805.
29. Mayer M. et al. 0203 Evaluating the needs of women living with metastatic breast cancer: A global survey. The Breast. 2009. Vol. 18. P. 70.
30. Mayer M. et al. Importance of Providing Tailored Resources to Patients with Metastatic Breast Cancer: Results of the Global BRIDGE Survey. Cancer Res. American Association for Cancer Research, 2009. Vol. 69, № 24 Supplements. P. 3085–3085.
31. Nielsen T.O. et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin. Cancer Res. 2004. Vol. 10, № 16. P. 5367–5374.
32. Niwińska A., Murawska M., Pogoda K. Breast cancer brain metastases: differences in survival depending on biological subtype, RPA RTOG prognostic class and systemic treatment after whole-brain radiotherapy (WBRT). Ann. Oncol. 2010. Vol. 21, № 5. P. 942–948.
33. O’Shaughnessy J. Extending survival with chemotherapy in metastatic breast cancer. Oncologist. 2005. Vol. 10, № 3. P. 21.
34. Olson E.M. et al. Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era. The Breast. NIH Public Access, 2013. Vol. 22, № 4. P. 525–531.
35. Parker J.S. et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J. Clin. Oncol. 2009. Vol. 27, № 8. P. 1160–1167.
36. Perou C.M. et al. Molecular portraits of human breast tumors. Nature. 2000. Vol. 406, № 6797. P. 747–752.
37. Quigley M.R. et al. The shifting landscape of metastatic breast cancer to the CNS. Neurosurg. Rev. 2013. Vol. 36, № 3. P. 377–382.
38. Robbins, S.L., Kumar, V., Cotran R.S. Robbins and Cotran pathologic basis of disease. 8th ed. Saunders, Philadelphia, PA, 2010. P. 1368.
39. Savci-Heijink C.D. et al. Retrospective analysis of metastatic behaviour of breast cancer subtypes. Breast Cancer Res. Treat. Springer, 2015. Vol. 150, № 3. P. 547–557.
40. Schrama J.G. et al. Randomized trial of high-dose chemotherapy and hematopoietic progenitor-cell support in operable breast cancer with extensive lymph node involvement: final analysis with 7 years of follow-up. Ann. Oncol. Oxford University Press, 2002. Vol. 13, № 5. P. 689–698.
41. Slamon D.J. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 2001. Vol. 344, № 11. P. 783–792.
42. Smid M. et al. Subtypes of breast cancer show preferential site of relapse. Cancer Res. 2008. Vol. 68, № 9. P. 3109.
43. Sørlie T. et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. U. S. A. 2001. Vol. 98, № 19. P. 10869–10874.
44. Voduc K.D. et al. Breast cancer subtypes and the risk of local and regional relapse. J. Clin. Oncol. 2010. Vol. 28, № 10. P. 1684–1691.
45. Witzel I. et al. Breast cancer brain metastases: biology and new clinical perspectives. Breast Cancer Res. BioMed Central, 2016. Vol. 18, № 1. P. 8.
Number of Views: 308
Category of articles:
Reviews
Bibliography link
Абильтаева А.А., Адылханов Т.А., Мысаев А.О. Молекулярный тип рака молочной железы, как прогностический фактор метастазирования (Обзор литературы) / / Наука и Здравоохранение. 2016. №4. С. 119-128. Abiltaeva A.A., Adylhanov T.A., Myssayev A.O. Molecular type of breast cancer as prognostic factor for metastasis (Literature review). Nauka i Zdravookhranenie [Science & Healthcare]. 2016, 4, pp. 119-128. Абильтаева А.А., Адылханов Т.А., Мысаев А.О. Метастазданған сүт безі ісігінің молекулярлық типтерінің болжау фактірлірі (Әдебиеттерге шолу) / / Ғылым және Денсаулық сақтау. 2016. №4. Б. 119-128.Related publications:
INTERRELATION OF INTRAABDOMINAL HYPERTENSION AND MARKERS OF GASTROINTESTINAL TRACT INJURY IN PATIENTS WITH MULTIORGAN DYSFUNCTION
DRUG-INDUCED LIVER INJURY AND GENDER DIFFERENCES
QUALITY OF LIFE IN PRIMARY BILIARY CHOLANGITIS AND ITS ASSESSMENT
DIAGNOSTIC AND THERAPEUTIC LAPAROSCOPY FOR ABDOMINAL INJURIES. REVIEW
METHODS FOR SCHOOL-AGE CHILDREN NUTRITIONAL STATUS ASSESSMENT: FOCUS ON ANTHROPOMETRIC PARAMETERS. A REVIEW.